Rabring7 degrades c-Myc through complex formation with MM-1

Area of Science:

• Molecular Biology
• Oncology
• Cellular Biology

Background:

• MM-1 is a novel c-Myc-binding protein that represses transcription and transforming activities of c-Myc.
• A specific mutation (A157R) in MM-1 abrogates its tumor-suppressive functions, and this mutation is observed in leukemia and lymphoma patients.
• MM-1 interacts with the ubiquitin-proteasome system to promote c-Myc degradation.

Purpose of the Study:

• To identify proteins that bind to MM-1.
• To elucidate the mechanism by which MM-1 and its binding partners regulate c-Myc.
• To investigate the role of Rabring7 in the context of MM-1 and c-Myc interactions.

Main Methods:

• Co-immunoprecipitation to identify MM-1 binding proteins.
• Ubiquitination assays to assess protein modification.
• Western blotting and immunofluorescence to detect protein levels and localization.
• Gene knockdown experiments to evaluate functional consequences.

Main Results:

• Rabring7 was identified as an MM-1 binding protein.
• Rabring7 mono-ubiquitinates MM-1 in the cytoplasm without causing its degradation.
• Rabring7 binds to and ubiquitylates c-Myc in a T58-dependent manner.
• Co-transfection of MM-1 and Rabring7 leads to c-Myc degradation.
• c-Myc degradation is blocked in MM-1 knockdown cells, even with Rabring7 transfection.
• Rabring7, MM-1, and c-Myc co-localize in the nucleus upon MM-1 and Rabring7 translocation.

Conclusions:

• Rabring7 stimulates c-Myc degradation through MM-1.
• MM-1 acts as a scaffold, facilitating Rabring7-mediated ubiquitination and subsequent degradation of c-Myc.
• This pathway represents a novel mechanism for regulating c-Myc stability and has implications for understanding tumor suppression in leukemia and lymphoma.